Eurocine Vaccines AB announces the completion of knowledge transfer and preparations for the development of the manufacturing process for the company´s chlamydia vaccine candidate. The process development activities initiated at Biovian according to schedule, are …
Annexin Pharmaceuticals AB and CDMO Biovian Oy released the First-In-Class ANXV drug candidate for clinical trials. Following a clinical study in healthy subjects, clinical trials with the drug will target retinal vein occlusion, a condition …
Affibody AB, a Swedish biotech company focused on developing next-generation biopharmaceuticals has selected Biovian Oy, the leading Nordic One-Stop-Shop CDMO for biopharmaceuticals as a CDMO partner for ABY-062 recombinant protein for clinical trial use. The …
Eurocine Vaccines AB has selected Biovian Oy, Turku, Finland, as the contract developer for the Company’s vaccine candidate against chlamydia. Biovian, which is an internationally recognized contract developer and manufacturer with its own GMP facility, …
Biovian is delighted to announce that Dr. Magnus Gustafsson has been appointed Head of Global Business Development. “We are very pleased that Magnus Gustafsson will assume the role of Head of Global Business Development at …
